Emerging drugs for the treatment of acromegaly.
Expert Opin Emerg Drugs
; 25(4): 409-417, 2020 12.
Article
em En
| MEDLINE
| ID: mdl-32938258
ABSTRACT
INTRODUCTION:
Acromegaly is a disease characterized by elevated growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. Surgery is the only curative treatment, while medical therapies are administered life-long. To date, almost 30% of patients treated with the currently available medical therapies do not achieve biochemical control. AREAS COVERED This review focuses on new drugs in development for acromegaly. In detail, we provide an overview of the new molecules designed to improve disease control rate (such as novel somotostatin receptor ligands and antisense oligonucleotides), as well as the new formulations of existing medications aiming to improve patients' compliance (e.g. oral or long-acting subcutaneous octreotide). EXPERT OPINION The constant progresses in the medical treatment of acromegaly could lead to an individualized therapy based on tumor, as well as patient's characteristics. Besides disease control, patient's need represents a major target of medical treatment in chronic diseases such as acromegaly, in order to improve compliance to therapy and patients' quality of life.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Acromegalia
/
Desenho de Fármacos
/
Desenvolvimento de Medicamentos
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Opin Emerg Drugs
Assunto da revista:
TERAPIA POR MEDICAMENTOS
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Itália